Schwartzberg S, et al. - In two randomized phase 3 studies with 1,450 cases receiving 5,969 chemotherapy cycles in Study 1 and 412 subjects receiving 1,961 chemotherapy cycles in Study 2, researchers estimated the effectiveness of oral netupitant-palonosetron 300/0.50 mg (NEPA) over numerous chemotherapy cycles in preventing chemotherapy-induced nausea and vomiting (CINV). They found that ≥75% of patients completed four or more cycles in each study. They reported oral NEPA was better than palonosetron in preventing CINV in the acute and delayed phases of cycle 1, with higher rates of complete response (CR), no emesis, and no significant nausea (NSN) reported across four cycles in Study 1. They observed numerically higher CR and NSN rates with oral NEPA in the acute and delayed phases vs aprepitant-palonosetron in moderately emetogenic chemotherapy/highly emetogenic chemotherapy cases in Study 2. In preventing both acute and delayed CINV over multiple chemotherapy cycles, oral NEPA was highly efficacious.